

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
 - TEXT CUT OFF AT TOP, BOTTOM OR SIDES
 - FADED TEXT
 - ILLEGIBLE TEXT
 - SKEWED/SLANTED IMAGES
 - COLORED PHOTOS
 - BLACK OR VERY BLACK AND WHITE DARK PHOTOS
-
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problems Mailbox.**

THIS PAGE BLANK (USPTO)



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent-Classification ⁴ : A61K 31/70, 31/21, 31/195 A61K 31/19, 31/18, 31/165 A61K 31/03	A1	(11) International Publication Number: WO 90/01937 (43) International Publication Date: 8 March 1990 (08.03.90)
(21) International Application Number: PCT/US89/03581 (22) International Filing Date: 24 August 1989 (24.08.89) (30) Priority data: 235,903 24 August 1988 (24.08.88) US (71) Applicant: RESEARCH TRIANGLE INSTITUTE [US/ US]; Cornwallis Road, Hanes Building, Research Tri- angle Park, NC 27709 (US). (72) Inventors: LEE, Yue-Wei ; Research Triangle Institute, Post Office Box 12194, Research Triangle Park, NC 27709-2194 (US). FANG, Qi-Cheng ; Institute of Mate- ria Medica, Chinese Academy of Medical Sciences, 1 Xi- an Nong Tan Street, Beijing (CN). WANG, Zhen-Guo ; LI, De-Hua ; Chang Baishan Institute of Materia Medi- ca, No. 3, First Alley Sheng-li Road, Teng Hua, Jilin (CN). COOK, C., Edgar ; Research Triangle Institute,		(74) Agents: LAVALLEYE, Jean-Paul et al.; Oblon, Spivak, McClelland, Maier & Neustadt, Fourth Floor, 1755 South Jefferson Davis Highway, Arlington, VA 22202 (US). (81) Designated States: AT (European patent), AU, BE (Euro- pean patent), CH (European patent), DE (European pa- tent), DK, FR (European patent), GB (European pa- tent), IT (European patent), JP, KR, LU (European pa- tent), NL (European patent), NO, SE (European patent). Published <i>With international search report.</i>
(54) Title: PENTACYCLIC TRITERPENOID COMPOUNDS AS TOPOISOMERASE INHIBITORS OR CELL DIFFER- ENTIATION INDUCERS (57) Abstract Pentacyclic triterpenoid compounds such as α -boswellic acid and its acetate, β -boswellic acid and its acetate, which have an inhibitory effect on topoisomerase I and topoisomerase II, are disclosed. Compositions based on the pentacyclic triterpenoid compounds which can be used to treat various cancers in mammals are also disclosed.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MR	Mauritania
BE	Belgium	GA	Gabon	MW	Malawi
BF	Burkina Fasso	GB	United Kingdom	NL	Netherlands
BG	Bulgaria	HU	Hungary	NO	Norway
BJ	Benin	IT	Italy	RO	Romania
BR	Brazil	JP	Japan	SD	Sudan
CA	Canada	KP	Democratic People's Republic of Korea	SE	Sweden
CF	Central African Republic	KR	Republic of Korea	SN	Senegal
CG	Congo	LI	Liechtenstein	SU	Soviet Union
CH	Switzerland	LK	Sri Lanka	TD	Chad
CM	Cameroon	LU	Luxembourg	TG	Togo
DE	Germany, Federal Republic of	MC	Monaco	US	United States of America
DK	Denmark				

-1-

Pentacyclic Triterpenoid Compounds As Topoisomerase
Inhibitors Or Cell Differentiation Inducers

Technical Field

- 5 This invention relates generally to pentacyclic
triterpenoid compounds such as α -boswellic acid
acetate, β -boswellic acid acetate and their analogs
which possess topoisomerase inhibitory, cell
differentiation inducing and/or anti-cancer activities.

10 Disclosure of the Invention

1. Introduction

DNA topoisomerases I and II are nuclear enzymes
which can mediate structural transitions in DNA and
chromatin by their ability to break and rejoin single
15 or double strands of DNA, respectively. These enzymes
can catalyze many types of interconversions between DNA
topological isomers. Examples are catenation and
decatenation and knotting and unknotting. DNA
topoisomerases have been found to affect a number of
20 vital biological functions including replication,
transcription, recombination and repair (Gellert, M.,
Ann. Rev. Biochem., 50, 879-910 (1981); Wang, J. C.,
Ann. Rev. Biochem., 54, 665-695 (1985); Cozzarelli, N.
R., Cell, 22, 327-328 (1980); and Liu, L. F., Crit.
25 Rev. Biochem., 15, 1-24 (1983)).

Topoisomerases have been isolated from a wide

-2-

variety of biological sources, such as bacteria, E. coli and M. luteus; bacteriophage, T4; yeast, Saccharomyces; insects, Drosophila; amphibians, Xenopus; and mammals, Hela cells, calf thymus, mouse
5 leukemia cells and human leukemic cells (Miller, K. G., et al., J. Biol. Chem. 256, 9334 (1987); Pommier, Y., et al., Biochem. 24, 6410 (1985)).

In the bacterium E. coli, a new type I topoisomerase, DNA topoisomerase III, has been found.
10 This enzyme, similar to the other type I enzymes, relaxes negatively supercoiled DNA (Wang, 1985).

One important feature of the mechanism of topoisomerases is their ability to form a covalent protein-DNA complex during the reaction. In the case
15 of topoisomerase I, this involves a phosphotyrosyl bond between the enzyme and the 3' terminus of the break site, while in the case of topoisomerase II, the phosphotyrosyl bonds are formed with the 5' termini. It is clear that through these actions on DNA topology
20 and the breaking and rejoining of DNA strands, the topoisomerases are involved in a diverse number of vital cellular processes (Vosberg, H. P., Current Topics in Microbiology and Immunology, p. 19, Springer-Verlag: Berlin (1985); Wang, J. C., Ann. Rev. Biochem,
25 54, 665-695 (1985)).

Thus, the development of chemical agents capable of modulating the enzyme activity of topoisomerases would have considerable value for manipulation of gene expression and chemotherapeutic intervention of cancer.

30 2. DNA Topoisomerases in Cancer Chemotherapy

-3-

Since 1980, DNA topoisomerases have emerged as target enzymes of considerable promise in cancer chemotherapy. Previously, antitumor drugs such as doxorubicin, daunorubicin, amsacine (m-AMSA) and mitoxantrone were believed to work by intercalating DNA, thereby blocking the orderly progression of DNA and RNA polymerases. However, this notion did not fully account for potency differences between various intercalating agents and did not account for the production of DNA breakage when cells were exposed to these agents. In addition, anticancer drugs such as epipodophyllotoxin (EPP), etoposide and teniposide do not intercalate into DNA. It is now believed that these drugs actually kill cells via their interaction with the nuclear enzyme DNA topoisomerases (Tewey, K. M., et al., J. of Biol. Chem., 259, 9182 (1984a); Tewey, K. M., et al., Science, 226, 466 (1984b); Rowe, T. C., et al., Cancer Res., 46, 2021 (1986)).

Fast growing evidence clearly suggests that topoisomerases I and II each have an important function in DNA replication and genetic processes via the formation of the "cleavable complex". Thus, inhibition of topoisomerases or stabilization of the topoisomerase-DNA "cleavable complex" may be interpreted as a form of DNA damage in the cell. Consequently, this damage induces the cell's effort to process or repair the cleavable complex and therefore activates the proteases whose expression is lethal and ultimately leads to the cells' death (Liu, L., National Cancer Institute Monographs (1987)).

a. Topoisomerase I Inhibitors

Topoisomerase I has become a target enzyme of considerable interest in recent drug development. For instance, camptothecin (CMT) has been shown to inhibit RNA and DNA synthesis in a variety of animal and human tumor cell lines in vitro (Bosman, H. B., Biochem. Biophys. Res. Commun., 41, 1412 (1970); Horwitz, M. S. and Horwitz, S. B., Biochem. Biophys. Res. Commun., 45, 723 (1971); Kessel, D., et al., Biochim. Biophys. Acta., 269, 210 (1972); Li, L. H., et al., Cancer Res., 32, 2643 (1972); Bhuyan, B. K., et al., Cancer Res., 33, 888 (1973); Drewinko, B., et al., Cancer Res., 34, 747 (1974)) and in vivo (Gallo, R. C., et al., J. National Cancer Institute, 46, 789 (1971); Neil, G. L., et al., Cancer Res., 33, 895 (1973)). The observations of a good correlation between inhibition of nucleic acid synthesis, DNA strand breakage and in vivo antitumor activity have led to the conclusion that effect on DNA was a primary determinant of cytotoxicity.

Recent interest in the possible use of CMT derivatives with improved therapeutic ratios has led to more extensive studies of their mode of cytotoxicity. Hsiang et al. (J. Biol. Chem., 260, 14873 (1985)) have reported that CMT blocks the rejoining step of the breakage-reunion reaction of topoisomerase I with DNA. CMT, which does not cleave purified DNA (Horwitz, M. S. and Horwitz, S. B., Biochem. Biophys. Res. Commun., 45, 723 (1971); Hsiang, Y. H., et al., J. Biol. Chem., 260, 14873 (1985)), induced site-specific cleavage of DNA in the presence of purified mammalian topoisomerase I (Castora, F. J. and Kelley, W. G., Proc. Natl. Acad. Sci. 83, 1680 (1986)) which

was linked to the 3' end of the broken DNA strands (Hsiang, Y. H., et al., J. Biol. Chem., 260, 14873 (1985)). Induction of strand breakage was immediate and reversible upon removal of the drug or incubation with 0.5 M salt. CMT did not intercalate into DNA, single or double stranded. It induced no DNA cleavage via purified mammalian topoisomerase II, nor did it inhibit the enzyme's catalytic activity (Hsiang, Y. H., et al., J. Biol. Chem., 260, 14873 (1985)). These data clearly indicate that CMT specifically inhibits mammalian topoisomerase I, and its cytotoxic effects may be explained by stabilization of a cleavable complex between enzyme and DNA, resulting in inhibition of nucleic acid synthesis and induction of DNA strand breaks.

b. Topoisomerase II Inhibitors

Recently, a number of clinically active antitumor drugs have been shown to enhance DNA cleavage by purified eukaryotic DNA topoisomerase II (Nelson, E. M., et al., Proc. Natl. Acad. Sci. USA, 81, 1361 (1984); Tewey, K. M., et al., J. of Biol. Chem., 259, 9182 (1984a); Tewey, K. M., et al., Science, 226, 466 (1984b); Ross, W., et al., Cancer Res., 44, 5857 (1984); Minocha, A., et al., Biochem. Biophys. Res. Commun., 122, 165 (1984)). For example, the intercalative aminoacridine derivative 4'-(9-acridinyl-amino)methansulfon-m-aniside (m-AMSA) markedly stimulates the breakage of DNA by mammalian DNA topoisomerase II at a concentration of 20 µg/mL (Nelson, E. M., et al., Proc. Natl. Acad. Sci. USA, 81, 1361 (1984); Rowe, T. C., et al., Cancer Res., 46, 2021 (1986)). Other intercalative and nonintercalative antitumor drugs including adriamycin,

5-iminodaunorubicin, ellipticine, 2-methyl-9-hydroxyellipticine and epipodophyllotoxins, VP-16 and VM-25, function similarly in vitro (Ross, W., et al., Cancer Res., 44, 5857 (1984); Minocha, A., et al., Biochem. Biophys. Res. Commun., 122, 165 (1984); Tewey, K. M., et al., J. of Biol. Chem., 259, 9182 (1984a); Tewey, K. M., et al., Science, 226, 466 (1984b); Chen, G. L., et al., J. Biol. Chem., 259, 13560 (1984)). This topoisomerase-mediated DNA breakage was directly demonstrated by Liu's group, who found that the drug caused the enzyme to be covalently linked to the 5' terminus of the break site upon denaturation.

Structure-activity relationship studies of closely related drug congeners provided strong support that both intercalating agents and EPP interact directly with the enzyme and potentiate the cleavable-complex formation (Silber, R., et al., Natl. Cancer Institute Monographs 4, 111 (1987)). Moreover, excellent correlations were observed between cytotoxicity and potency with respect to cleavable complex formation in vivo and in vitro (Rowe, T. C., et al., Cancer Res., 46, 2021 (1986); Long, B. H., et al., Biochemistry, 23, 1183 (1984); Levin, M., et al., Cancer Res., 41, 1006 (1981); Zwelling, L. A., et al., Biochemistry, 20, 6553 (1981); Nelson, E. M., et al., Proc. Natl. Acad. Sci. USA, 81, 1361 (1984)).

These topoisomerase-mediated DNA breaks are postulated to be responsible for the drug's cytotoxicity.

3. Cell Differentiation in Cancer Chemotherapy

Cancer can be considered a disorder of cell differentiation (Pierce, G., et al., Cancer, A Problem of Developmental Biology, Englewood Cliffs, Prentice Hall, 1978; Greaves, M. F., J. Cell Physiol., 1, 113-125 (1982)), which is readily illustrated by the hematologic neoplasms. Oncogenic conversion, defined as the arrest of differentiation without loss of proliferative capacity can occur at any of the intermediate maturation steps. Consequently, the maturation-arrested cells continue to proliferate, a population of immature "cancer" cells emerges and gives rise to adverse clinical manifestations (Bloch, A., Cancer Treatment Reports, 68, 199 (1984)).

Under normal conditions, proliferation and maturation are regulated by growth factors (GF) and differentiation factors (DF), respectively. The neoplastic cell can be derived from events that alter the cell's sensitivity to these factors. These changes may entail increased sensitivity to GF, decreased responsiveness to DF, decreased elaboration of DF by the host and endogenous production of GF by the neoplastic cell itself (Todaro, G. I., Fed. Proc., 41, 2987 (1982)).

Almost all clinically effective anticancer agents are inhibitors of DNA synthesis or transcription (Bloch, A., Purine and Pyrimidine Analogs in Cancer Chemotherapy in New Leads in Cancer Therapeutics (E. Mihich, ed.), Boston, G. K. Hall and Co., 1981, pp. 65-72). The notion that the antitumor activity results from the ability of DNA-targeted agents to induce the maturation of sensitive cancer cells past

the stage of oncogenic differentiation arrest, thereby removing their capacity for unlimited proliferation, is implicated in recent studies (Takeda, K., et al., Cancer Res., 42, 5152-5158 (1982)). These studies
5 clearly demonstrate that only DNA-specific inhibitors such as daunorubicin or cytarabine are capable of effectively inducing the differentiation of various myeloid leukemic cell lines.

4. Boswellic Acids

10 Frankincense (Olibanum), a costly resin produced by members of the genus Burseraceae, has been widely used in perfumery, for religious purposes and as a folk medicine in the treatment of several diseases,
15 including inflammation and arthritis [Chinese Herbal Dictionary, 1, 1379-1381 (1977); Yadav, D. S., et al., Abstracts of Papers Presented at the Scientific Session "Medical Chemistry", Indian Pharmaceutical Congress, Bangalore, February, 1985]. Results of chemical
20 examination have shown it to contain a number of compounds, including α -boswellic acid, β -boswellic acid, acetyl α -boswellic acid, other triterpenoid carboxylic acids, and macrocyclic diterpenoids such as incensole, incensole oxide and isoincensole oxide
(Winterstein, A., et al., Physiol. Chem., 208, 9
25 (1932); Chem. Abstr., 26, 4321 (1932); Simpson, J. C. E., et al., J. Chem. Soc., 686 (1938); Beton, J. L., et al., J. Chem. Soc., 2904 (1956); Corsano, S., et al., Tetrahedron, 23, 1977 (1967); Nicoletti, R. and Forcellese, M. L., Tetrahedron, 24, 6519 (1968);
30 Nicoletti, R., Forcellese, M. L., and Petresi, U., Tetrahedron, 28, 325 (1972); Nicoletti, R., Santarelli, C., and Forcellese, M. L., Tetrahedron Lett., 3783 (1973)). It has now been reported that its anti-

inflammatory and antiarthritic activities are due to the presence of α -boswellic acid and other related triterpenoid carboxylic acids (Yadav, D. S., et al., Abstracts of Papers Presented at the Scientific Session
5 "Medical Chemistry", Indian Pharmaceutical Congress, Bangalore, February, 1985). In spite of these activities, up to now, no one has recognized that a triterpenoid compound could inhibit any topoisomerase or cause cell differentiation.

10 Accordingly, one object of the present invention is to provide compositions which are capable of inhibiting topoisomerase I in vitro and in vivo.

Another object of the present invention to provide compositions which are capable of inhibiting
15 topoisomerase II in vitro and in vivo.

Another object of the present invention is to provide compositions which are capable of inducing cellular differentiation, particularly differentiation of cells past the stage of oncogenic differentiation.

20 It is yet another object of the present invention to provide a method of inhibiting topoisomerase I in vitro and in vivo.

Another object of the present invention is to provide a method for inhibiting topoisomerase II
25 in vitro and in vivo.

Yet another object of the present invention is to provide a method for inducing cellular differentiation past the stage of oncogenic differentiation.

-10-

Another object of the present invention is to provide compositions for treating various cancers.

Another object of the present invention is to provide a method for treating various cancers.

5 These and other objects of the present invention as will hereinafter become more readily apparent have been achieved by discovering that certain pentacyclic triterpenoid compounds, including α -boswellic acid, β -boswellic acid, and acetyl α -boswellic acid,
10 and other derivatives of these compounds, have abilities to inhibit topoisomerase I and topoisomerase II, and to induce cellular differentiation in vitro and, it is expected, in vivo. Significantly, it has been demonstrated that compositions based on these
15 molecules have potent anti-cancer activity in tumor-bearing mice. As a result, anti-cancer activity is expected in other mammals, including humans.

Brief Description Of The Drawings

20 A more complete appreciation of the invention and many of the attendant advantages thereof will be readily obtained as the same becomes better understood by reference to the following detailed description when considered in connection with the accompanying drawings, wherein:

25 Figure 1 shows the structures of α -boswellic acid acetate (A-1), α -boswellic acid (A-2), β -boswellic acid acetate (B-1) and β -boswellic acid (B-2).

Figure 2 shows the structure of β -boswellic acid acetate in the crystalline state as revealed by X-ray

crystallography.

Figure 3 shows the generic structures of triterpenoids of the present invention. R¹-R⁷ are identified herein.

5 Figure 4 shows a separation scheme of oleogum resin exudate from Boswellia carterii Birdw.

Figure 5 shows a gel electrophoresis analysis of topoisomerase I relaxation of DNA.

10 Figure 6 shows a gel electrophoresis analysis of topoisomerase II unknotting of DNA.

Best Mode For Carrying Out The Invention

The Chinese herbal medicine Tian-Shian-Wan has been reported in Chinese clinical studies to have antitumor activity. No information was available as to individual chemicals present in this complex mixture of natural materials nor as to which parts of it were responsible for the reported antitumor activity. In an attempt to confirm this activity and provide a biological and biochemical basis for the reported clinical observations, a sample of this medicine (prepared from a mixture of natural sources) was subjected to extraction and separated into fractions.

25 Testing of the fractions against topoisomerase I enzyme purified from chronic human leukemic cells showed that potent inhibitory activity was present in only one of the fractions. This fraction was further purified to give a crystalline material shown by HPLC to consist of two distinct compounds. Mass spectral

-12-

analysis showed the two compounds to be isomeric and gave a molecular formula $C_{32}H_{50}O_4$. From this and knowledge of the Chinese herbal medicine literature, it was possible to postulate the two compounds to be the acetates of α - and β -boswellic acid (A-1 and B-1 in Figure 1), respectively.

The exudative resin from Boswellia carterii Birdw containing these two compounds was then obtained, and they were isolated as shown in Figure 4 and shown to be identical with the materials from Tian-Shian-Wan. The structures of the compounds were established by mass spectrometry, which gave the molecular formula and showed a highly characteristic retro-Diels Alder fragment in addition to other characteristic peaks. NMR spectra, including determination of two dimensional carbon-hydrogen correlation spectra and carbon-13 NMR spectra, were also in accord with the structures shown. X-ray crystallography studies have also confirmed the structure of the β -boswellic acid acetate. Moreover, 2D-NMR of α -boswellic acid acetate is in accord with structure A-1.

Both α - and β -boswellic acid acetates were tested for their ability to inhibit topoisomerase I and topoisomerase II according to the procedures of Hsiang et al. (1985). Very surprisingly in view of their non-aromatic structures, both boswellic acid acetate isomers were highly active against topoisomerase I and II (see Figures 5 and 6). The α -isomer A-1 is the more potent of the two forms and is more potent than the standard compound, camptothecin, in the topoisomerase I inhibition assay. The isomers A-1 and B-1 are equipotent in topoisomerase II inhibition and are more potent than the standard compound VP-16-213

(Etoposide), which shows significant clinical activity against small-cell lung cancer, testicular cancer, lymphoma and leukemia (O'Dwyer, P., et al., Etoposide (VP-16-213), Current Status of an Active Anti-cancer
5 Drug, New Engl. J. Med. 312, 692-700 (1985)).

The study of the compounds at the Institute of Materia Medica in Beijing, PRC, has also shown that they induce differentiation in HL-60 cells at a concentration of 10 μ g/ml (see Example 4).

10 More significantly, these in vitro activities are in accordance with an animal study at the Institute of Materia Medica in which four out of ten tumor (L-1210) bearing mice survived while all of the mice in the control group died (see Example 5).

15 As described above, the boswellic acid compounds have three hitherto unreported properties which should be of significant medical advantage. These are their inhibition of topoisomerase I, inhibition of topoisomerase II, and ability to induce cell
20 differentiation. All three of these properties are important in anticancer drugs.

The presence and properties of topoisomerases in cells are relatively recent discoveries. In view of the extreme importance of transcription, recombination,
25 and repair of DNA in cell growth, replication, and function, it seems likely that other possible applications of topoisomerase inhibitors may appear as more is learned about these enzymes.

The compounds of this invention differ markedly
30 from known inhibitors of the enzymes in being

-14-

nonaromatic in character. In addition, as illustrated above, they are more potent than camptothecin and VP-16. They thus represent a novel structural type which may not exhibit some of the toxic side effects of the currently known compounds. Both scientifically and practically, this is a remarkable and unexpected finding.

Thus, in accordance with the present invention, it has been discovered unexpectedly that α -boswellic acid acetate, β -boswellic acid acetate and their analogs are potent topoisomerase I and II inhibitors and are capable of induction of cell differentiation at low concentration. This invention discloses for the first time that pentacyclic triterpenoids can exhibit strong topoisomerase I and II inhibitory activities and cell differentiation induction properties.

The triterpenoids of the present invention comprise compounds having structures C and D of Figure 3,

wherein R^1 is $-\text{COOR}^4$, where R^4 is a mono; di; or trisaccharide; $-\text{H}$; C_{1-4} alkyl; C_{2-4} alkenyl; C_{3-4} alkynyl; C_6-C_8 aryl which is unsubstituted or is substituted by halogen, methoxy, ethoxy, sulfonamido, amino, mono- or di- C_{1-4} -alkyl-amino, mono- or di-acetylamino, C_{1-4} alkyl, C_{2-4} alkenyl;

or

R^1 is $-\text{CONH}_2$; $-\text{CONHR}^5$; or $-\text{CONR}_2^5$, where R^5 is a mono; di; or trisaccharide; $-\text{CH}_3$; $-\text{CH}_2\text{COOH}$; $-\text{CH}_2\text{CH}_2\text{COOH}$; C_{2-8} alkyl; C_{2-8} alkenyl; C_{2-8} alkynyl; C_{6-8} aryl which is unsubstituted or is substituted by

-15-

halogen, methoxy, ethoxy, sulfonamido, amino, mono- or di-C₁₋₄-alkyl-amino, mono- or di-acetylamino, C₁₋₄ alkyl, or C₂₋₄ alkenyl, and

R² and R³ may be combinations of hydrogen or R⁵,

5 with -H, -OR⁴, -NH₂, -NHR⁵, -NHR₂⁵, $\overset{\text{O}}{\parallel}$ -OCR⁵ or $\overset{\text{O}}{\parallel}$ -NHCR⁵, wherein R⁴ and R⁵ are as defined above,

or

R² and R³ together may be =O or =N-OR⁴, wherein R⁴ is as defined above, and

10 R⁶ and R⁷ may be combinations of hydrogen or R⁵,

with -H, -OR⁴, -NH₂, -NHR⁵, -NHR₂⁵, $\overset{\text{O}}{\parallel}$ -OCR⁵ or $\overset{\text{O}}{\parallel}$ -NHCR⁵, wherein R⁴ and R⁵ are as defined above,
or

15 R⁶ and R⁷ together may be =O or =N-OR⁴, wherein R⁴ is as defined above.

As examples of C₁₋₄ alkyl groups, there may be mentioned methyl, ethyl, propyl, butyl, sec-butyl, and tert-butyl. As C₂₋₈ alkyl, there may in addition be mentioned pentyl, hexyl, heptyl, and octyl. For
20 C₂₋₄ alkenyl, there may be mentioned ethenyl, 1-propenyl, and 2-propenyl. As C₂₋₈ alkenyl, there may in addition, be mentioned 1-pentenyl. Analogous alkynyl groups are also contemplated.

For aryl, there may be mentioned a phenyl group or

-16-

a phenyl group substituted by halogen, O-C₁₋₄-alkyl, sulfonamido, amino, C₁₋₄-alkyl amino, or acetylamino.

For mono, di or trisaccharides, there may be mentioned glucosyl, galactosyl, fructosyl, and the
5 like.

Preferred groups for R¹ are -COOH, -COOCH₃, -COOC₂H₅ and -CONH₂.

Preferred groups for R² when R³ is -H are -H, -OH, -OAc, -OCOC₂H₅, and -NHAc.

10 When R² is -H, R³ is preferably -H, -OH, -OAc, -OCOC₂H₅, or -NHAc; or R²R³ is =O, =NOH, or =NOCH₃.

Preferred groups for R⁶ and R⁷ are the same as those of R² and R³.

Preferred are combinations wherein R¹ is -COOH or
15 -COOCH₃, either R² or R³ is -H and the other is -OH, -OAc, -OCOC₂H₅ or -NHAc and R⁶ = R⁷ = -H.

Also preferred are combinations in which R¹ is -COOH or -COOCH₃, either R² or R³ is -H and the other is -OH, -OAc, -OCOC₂H₅ or -NHAc and either R⁶ or R⁷ is
20 H and the other is -OH, -OAc, or -OCOC₂H₅.

Also preferred are combinations in which R¹ is -COOH or -COOCH₃, either R² or R³ is -H and the other is -OH, -OAc or -OCOC₂H₅, and R⁶R⁷ is =O, =NOH or =NOCH₃.

25 Particularly preferred are combinations in which R¹ is -COOH or -COOCH₃, R³ is -H and R² is -OH, -OAc or

-17-

-OCOC₂H₅, and R⁶ and R⁷ are -H.

Most particularly preferred are combinations in which R¹ is -COOH, R² is -OH, -OAc or -OCOC₂H₅, and R³, R⁶ and R⁷ are H.

5 As used herein, halogen, means preferably Cl, Br, I or F.

Also included within the scope of the present invention are pharmaceutically acceptable salts of salt-forming compounds falling within the scope of the
10 above description. In particular, when an anionic group is present on the molecule, any of the well-known pharmaceutically acceptable cations may be associated therewith. Thus, for example, sodium, potassium, calcium and quaternary amine salts, including ammonium,
15 could be employed. Preferably, sodium and potassium salts are employed. Furthermore, when a group capable of forming a cation is present on the molecule, a pharmaceutically acceptable anion may be associated therewith. Examples of such anions are acetate,
20 aspartate, benzoate, fumarate, ethanesulfonate, hydrochloride, lactate, oxalate, tosylate, etc. Of these salts, simple inorganic salts, such as salts of the hydrogen halides are preferred.

The present invention is also directed to pro-drug
25 compounds analogous to the active compounds disclosed herein. Such compounds are generally themselves be inactive or low in activity, but are converted in vivo into active compounds. Thus, for example, pro-drugs such as the methyl ester of any acid functionality
30 which is not active per se or has very low activity could be hydrolyzed, either uncatalytically or

-18-

catalytically with an enzyme such as an esterase, to an active compound such as boswellic acid. Such pro-drug compounds could well be the preferred therapeutic form of the present compounds. These analogous pro-drug compounds can be produced from active compounds based on procedures and factors which are well known to those of ordinary skill in the art. Accordingly, as used in the present application, "pro-drug analog" means "a chemical which is relatively non-toxic and pharmacodynamically inert but which can be transformed in vivo to a pharmacologically active drug" (Connors, T. A., *Xenobiotica*, 16:975 (1986)). More specifically it means a derivative or analog of the triterpenoids of the present invention which have relatively low or no ability to inhibit topoisomerase I or II or to cause cell differentiation or to kill cancer cells, until converted in the body to a derivative or analog with such ability or abilities. Such pro-drug compounds should have favorable properties such as enhanced absorption, water solubility, lower toxicity, or better targeting to the tumor cell (such as by reason of greater affinity for the tumor cell or a larger quantity of activating enzyme in the tumor cell as opposed to a normal cell so that larger concentrations of the active compound are produced in the tumor cell). Examples of such compounds are esters such as methyl, ethyl, phenyl, N,N-dimethylaminoethyl, acyl derivatives such as benzoyl, p-N,N-dimethylamino-benzoyl, N,N-dimethylaminoglycyl, peptide derivatives such as γ -glutamyl, glycyl, D-Val-Leu-Lys (cf. Chakravarty, P. K., et al., *J. Med. Chem.*, 26:663 (1983)), or glycoside derivatives such as glucuronides (cf. Connors, T. A. and Whisson, M., *Nature* 210:866 (1966)).

Standard procedures such as esterification, hydrolysis, amidation of carboxylic acids or esters or oxidation, reduction or organometallic (e.g. Grignard) reactions, lead to the substituents R^1 , R^2 and R^3 .

5 Allylic oxidation or bromination yields compounds in which $R^6, R^7 = H, OH; H, Br; \text{ or } =O$ followed by standard procedures of oxidation, reduction, esterification or nucleophilic displacement leading to the substituents R^6 and R^7 . Compounds in which R^2R^3 or R^6R^7 are $=O$ can

10 be converted to oximes or alkoximes by standard procedures.

The active (i.e. non-pro-drug) compounds of the present invention have K_i 's with topoisomerases I and II, as determined by the method of Hsiang (1985), and

15 as exemplified in the example below, of 50 micromolar or less. Preferably, the K_i will be from one nanomolar to 20 micromolar. Accordingly, as used herein, "inhibitory effective amount" of one of the present compounds means an amount of the composition sufficient

20 to result in 50-100% inhibition of the enzyme, preferably 70-100% inhibition, as determined by an in vitro test using a compound having the desired K_i value.

The active (i.e. non-pro-drug) compounds of the present invention have cell differentiation inducing ability in HL 60 cells, as determined by the method of Lu and Han, 1986 and exemplified in the example below, at concentrations of 100 μg per ml or less. Preferably the effective concentration will be from 1 ng to 100 μg

30 per ml, particularly preferably from 0.1 to 50 μg per ml. As used herein, "effective amount for differentiation" of one of the present compounds means an amount of the composition sufficient to result in

-20-

25-100% cell differentiation, preferably 50-100% cell differentiation, as determined by an in vitro test using a compound having the desired effective cell differentiation concentration.

5 Compounds having inhibitory activity against either or both of topoisomerase I or topoisomerase II are covered by this invention. It will also be understood that such compounds may be used to inhibit not only the topoisomerase I and II enzymes currently
10 known to those skilled in the art, but also may be used to inhibit other known or to be discovered isoenzymes of this type and other topoisomerase enzymes (DNA gyrases) having related activity, as will be apparent to one skilled in the art.

15 Likewise, the compounds of this invention may be used to induce cell differentiation in other cells than those of the present example, as will be apparent to one skilled in the art.

20 A compound having a structural formula as described in the present application may possess only one of the activities described herein. Such a compound is still part of the present invention. Thus, for example, a given compound may exert topoisomerase I inhibitory ability and not topoisomerase II inhibitory
25 ability. Similarly, a compound of the present invention may induce cell differentiation but not inhibit either of the two topoisomerase enzymes. Such compounds are part of the present invention, as are compounds possessing any combination of the activities
30 described herein.

DNA topoisomerase I was originally identified from

Escherichia coli as a single enzyme activity capable of relaxing supercoiled DNA (Wang, 1971). Subsequently, topoisomerase I activity from many eukaryotic cells has been isolated (Champoux and Dulbecco, 1972; Dynan et al., 1981; Liu and Miller, 1981; Castora, 1986). The enzyme has no requirement for a high-energy cofactor such as ATP or NAD. It acts by forming a covalent enzyme-DNA intermediate. This transient DNA break allows changes of linking number between the two strands of DNA. The topoisomerase I enzyme is a monomeric protein of approximate molecular weight 100 kDa, and relaxes both negatively and positively supercoiled DNA. It has been firmly established that, unlike the prokaryotic enzyme which binds to the 5' end, eukaryotic topoisomerase I forms a covalent intermediate with the 3' end of the broken DNA via a tyrosine residue (Gellert, 1981; Liu, 1983; Wang, 1985).

Topoisomerase II has been isolated from E. coli and eukaryotic organisms (Baldi, 1980; Hsieh, 1980) such as calf thymus and human HeLa cells (Liu, 1981; Glisson, 1984). Eukaryotic topoisomerase II is a homologous dimer with a molecular weight of 300 kDa (Liu et al., 1980).

The eukaryotic type II topoisomerase yields an identical cleavage site at the 5' ends (Sander, 1983).

Direct evidence that some anti-cancer drugs enhance DNA cleavage by purified eukaryotic DNA topoisomerase II has been reported (Nelson, 1984; Tewey, 1984; Ross, 1984; and Minocha, 1984).

Specific cancers which may be mentioned as

-22-

susceptible to treatment by administration of compounds in accordance with the present invention include small cell lung cancer, testicular cancer, lymphoma and leukemia (based on analogous VP-16 activity);

5 esophageal cancer, and stomach cancer; colon cancer (based on analogous activity with camptothecin); breast cancer; cancers of the central nervous system (based on likelihood that the compounds will cross the blood brain barrier); liver cancer; and prostate cancer.

10 Other cancers may also be susceptible to treatment with these compounds, and such activity can be readily measured using standardized tests including activity against tumor implants in nude, athymic mice models, known to those of ordinary skill in the art. Cells

15 associated with these cancers comprise examples of cells in which differentiation can be induced using compounds or compositions of the present invention.

Other compounds having topoisomerase I or topoisomerase II inhibitory activity have use in the

20 treatment of cancer in humans and nonhuman mammals (Rose, K. M., FASEB J. 2, 2474-2478, 1988). Chemical compounds capable of modulating topoisomerase enzyme activity have considerable value for recombination of DNA in gene manipulations as well.

25 By non-human mammals, is meant, for example, dogs, cats, monkeys, cows, horses, etc. Although the enzymes contained in these mammals may not be exactly the same as topoisomerase I or topoisomerase II isolated from a human source, if their function is generally the same

30 in these non-human mammals as in humans, and inhibition is detectable by a standard assay (such as those identified herein), then the inhibitory effect is within the scope of the compositions and methods of the

present invention.

Some clinically effective anticancer agents such as daunorubicin or cytarabine are capable of effectively inducing the differentiation of various myeloid leukemic cells, thus compounds possessing cell differentiation induction properties have use in anticancer purposes.

The compounds of the present invention may be administered by oral, parenteral, or intravenous routes, or by absorption through skin or mucous membrane surfaces using methods known to those skilled in the art of drug delivery.

For the purposes of therapeutic administration, the active ingredient may be incorporated into a solution or suspension.

The solutions or suspensions may also include the following components: a sterile diluent such as water for injection, saline solution, polyethylene glycols, glycerin, propylene glycol or other synthetic solvents; proteins such as serum albumin to enhance solubility; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. The preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.

-24-

The compositions containing the active compounds of the present invention can be formulated so as to be specifically targeted to tumors. For example, any of the various compounds of the present invention could be covalently attached to a monoclonal antibody which is directed to a tumor-associated antigen. Such linkages could be made through peptide bond formation with amino groups of an antibody. More preferably, such linkages should contain a disulfide moiety or other readily cleaved moiety, such as is described by Vitetta et al. (E. S. Vitetta, R. Jerrold Fulton, Richard D. May, Mark Till, Jonathan W. Uhr, Science, 238:1098 (1987), designed such that the compound released by the cleavage of the disulfide link is rapidly converted to the active topoisomerase inhibitor or cell differentiation inducer. Alternatively the compounds of this invention could be attached to or incorporated into liposomes, which are known to be useful for targeting anticancer drugs (G. Gregoriadis, J. Senior and A. Trouet, Editors, Targeting of Drugs, NATO Advanced Study Institute Series, Vol. 47, Plenum Press, New York, 1982). Liver cancer is especially susceptible to liposome targeting. Procedures for the preparation and use of such liposomes are discussed in the book by Gregoriadis et al.

Hence, as used herein, agents for targeting the compounds of the present invention to cancerous sites, include monoclonal antibodies specific to the cancerous site, liposomes which are preferentially adsorbed to the cancerous site, and other agents known to those of ordinary skill in the art which are preferentially attracted to or absorbed into cancerous sites. Such agents are described in, for example, Ghose, T., et al., Antibody-Linked Cytotoxic Agents in the Treatment

of Cancer: Current Status and Future Prospects,
J. Natl. Cancer Inst. 61 (1978). The amount of the
targeting agent can be determined by one of ordinary
skill in the art without undue experimentation. In
5 general, when the targeting agent is a monoclonal
antibody or another cytotoxic agent which is covalently
attached to the compound according to the present
invention, an approximately equimolar or less amount of
the targeting agent will be utilized. However, it is
10 also possible for different molar ratios of the present
compounds and the covalently attached agents to be
utilized.

Specific examples of monoclonal antibodies which
might be used in accordance with the present invention
15 and associated cancers which could be targeted by the
present compounds are the following:

-26-

Monoclonal Antibodies			
PRODUCT	COMPANY	INDICATION	STATUS
Panorex MAB	Centocor (Malvern, Pa.)	colorectal cancer, pancreatic cancer	Phase II
Ovarian RT MAb	Centocor (Malvern, Pa.)	ovarian cancer	Phase I
MAB	Cetus (Emeryville, Ca.)	breast cancer	Phase I
MAB	Damon (Needham Heights, Mass.)	lung cancer	Phase I
KS 1/4-DAVLB MAb	Eli Lilly (Indianapolis, Ind.)	cancer	in clinical trials
MAB-L6	Bristol-Myers/ Oncogen (New York, N.Y.)	lung cancer	Phase I
MAB	Immunomedics (Newark, N.J.) Johnson & Johnson (New Brunswick, N.J.)	colorectal cancer	Phase I

-27-

Other monoclonal antibodies could also be used, as long as they are targeted to specific cancerous sites, e.g. tumors.

Compounds of the present invention may also be administered in combination with other therapeutic treatments, such as radiation therapy for cancer, or in combination with other anticancer drugs, for example, cytotoxic drugs or other topoisomerase inhibitors or cell differentiation inducers.

While dosage values will vary with the specific severity of the disease condition to be alleviated, good results are achieved when the compounds described herein are administered to a subject requiring such treatment as an effective oral, parenteral or intravenous dose. The appropriate dose may be estimated from the effective amount of the compounds, the described in vitro tests and the bioavailability of the compounds described by the route administered, so as to produce an effective concentration of the compounds described at the target site in the body of the subject.

It is to be understood, however, that for any particular subject, specific dosage regimens should be adjusted to the individual need in the professional judgment of the person administering or supervising the administration of the aforesaid compound. It is to be further understood that the dosages set forth do not limit the scope or practice of the invention. The dosages may be administered at once, or may be divided into a number of smaller dosages to be administered at varying intervals of time.

-28-

Other features of the invention will become apparent in the course of the following descriptions of exemplary embodiments which are given for illustration of the invention only and are not intended to be
5 limiting thereof.

Examples

Example 1 - Isolation and Purification of α - and β -Boswellic Acid Acetate

As shown in Figure 4, the resin (290 g) was
10 exhaustively extracted with 70% aqueous acetone in a percolator to yield a crude extract (248.8 g, 85.7%). The crude extract was treated with methylene chloride, and the methylene chloride soluble fraction was concentrated (194.8 g, 65.1%). This crude mixture was
15 chromatographed over silica gel by using increasing amounts of acetone in methylene chloride as the eluent.

From methylene chloride eluants, a crude mixture of α - and β -boswellic acid acetate (16 g) was obtained. After repeated chromatography and
20 recrystallization in methanol, fine colorless needle crystals (4.54 g) were obtained. HPLC analysis indicated that the crystalline material was still a mixture, consisting of α - and β -boswellic acid acetates in an approximately 1:1 ratio.

25 0.25 g of the isomeric mixture was chromatographed over a C-18 reversed phase column (25 mm x 30 cm) by using 92% aqueous methanol as the mobile phase. Fractions containing pure α - and β -boswellic acid acetate (determined by HPLC analysis) were combined and
30 concentrated, respectively. Further recrystallization

from methanol provided 5 mg of α -boswellic acid acetate (A-1) and 11 mg of β -boswellic acid acetate (B-1).

Identification of α -Boswellic Acid Acetate
and β -Boswellic Acid Acetate

- 5 The structures of α - and β -boswellic acid acetates were confirmed based on the following physical and spectral analysis.

α -Boswellic Acid Acetate

- 10 Colorless needles, $[\alpha]_D^{22} + 66.2^\circ$, HRMS 498.3697, $C_{32}H_{50}O_4$, calculated 498.3709. Its IR spectrum showed carbonyl bands at 1734 cm^{-1} for acetoxy and 1692 cm^{-1} for the carboxyl group. The EI mass spectrum showed peaks at m/z 280, 218, which represent the characteristic retro-Diels-Alder cleavage peaks from
15 ring-C of Δ^{12} -oleanene/ursene derivatives. Its ^1H NMR spectrum showed eight methyl signals (cf. Table I). Its ^{13}C NMR spectrum revealed thirty-two carbon signals.

β -Boswellic Acid Acetate

- 20 Colorless needles, $[\alpha]_D^{22} + 60.0^\circ$, HRMS 498.3701, $C_{32}H_{50}O_4$, calculated 498.3709. Its IR spectrum showed carbonyl bands at 1733 cm^{-1} for acetoxy and 1693 cm^{-1} for the carboxyl group. The EI mass spectrum showed the characteristic peaks as in α -boswellic acid
25 acetate. Its ^1H NMR spectrum also showed eight methyl signals (Table I). Its ^{13}C NMR spectrum revealed thirty-two carbon signals.

X-ray diffraction analysis (cf. Figure 2)
confirmed the structure of β -boswellic acid acetate.

TABLE I

5

Chemical Shift of the Me Groups (ppm from TMS)
for α - and β -Boswellic Acid Acetate

	23 Me	25 Me	26 Me	27 Me	28 Me	29 Me	30 Me	-CO-CH ₃
α -Boswellic Acid Acetate	0.90	1.01	1.19	1.24	0.84	0.87	0.87	2.09
10 β -Boswellic Acid Acetate	0.91	1.05	1.12	1.25	0.81	0.81	0.91	2.10

Example 2 Topoisomerase I Inhibitory Activity

Topoisomerase I inhibitory activity was monitored
15 by using the supercoiled pBR 322 DNA relaxation assay
according to a published procedure [Liu et al., Proc.
Natl. Acad. Sci., U.S.A., 76, 3487 (1987)].

DNA topoisomerase I was purified to homogeneity
from chronic human leukemic cells. Plasmid pBR 322 DNA
20 was purified by phenol deproteinization of cleared
lysates followed by CsCl/ethidium isopycnic
centrifugation and gel filtration. The topoisomerase I
inhibitory activities of compounds A-1 and B-1 are
summarized in Figure 5. The α isomer A-1 showed higher
25 potency (~3X) than standard camptothecin. The β isomer
B-1 showed comparable potency to standard camptothecin.

Example 3 Topoisomerase II Inhibitory Activity

Topoisomerase II activity was monitored by using the P₄ unknotting assay [Liu et al., Nucleic Acid Res., 9, 3979 (1981)]. Naturally knotted DNA isolated from the tailless capsids of a phage was used as the substrate. Topoisomerase II was purified from human leukemic cells. Both isomers A-1 and B-1 showed higher potency than standard VP-16. The results are summarized in Figure 6.

10 Example 4 Cell Differentiation Induction Activity

Cultured human promyeloid leukemia cell lines, HL-60, were induced by an approximate 1:1 ratio mixture of compounds A-1 and B-1 to differentiate into mature cells. Cell differentiation was assessed by the procedure of Lu and Han [Lu, Y. and Han, R., Differentiation of Human Promyelocytic Cells (HL-60) Induced by Aclacinomycin B, Acta Academia Medica Sinica, 8(37), 211-214 (1986)]. Duplicate cultures were carried for each of 5 culture days in the presence of the test mixture drug at various concentrations (see Table II).

Table II
EFFECT ON HL-60 CELLS

	Concentration (μ g/ml) *	NBT Reduction % **
5	1	2.5
	8	27.0
	10	51.0

* Mixture of A-1 and B-1 in ca. 1:1 ratio.

** Increase over control cells in ability to reduce NBT.

10 Example 5: In vivo Antitumor Activity

The effect of the compounds on L-1210 leukemia was determined by administering a 1:1 mixture of α -boswellic acid acetate and β -boswellic acid acetate to CDF-1 mice. L-1210 cells (1×10^6 cells/mouse) were
15 implanted intraperitoneally into CDF-1 mice (10 mice/group) on day 0 and intraperitoneal treatment with the compounds was initiated on day 1 for 12 days. The results are summarized in Table III.

Table III

ACTION OF BC-4* ON L-1210 BEARING MICE (IN VIVO)

5	<u>Group</u>	<u>Animal Number</u>		<u>Body Weight</u>		<u>Average Survival Time (Days)</u>
		<u>Initial</u>	<u>Final**</u>	<u>Initial</u>	<u>Final</u>	
	Control	16	0	17.0	19.7	15.7 ± 1.9
	50 mg/kg	10	1	16.9	17.8	16.9 ± 6.1
	100 mg/kg	10	4	16.7	17.4	22.9 ± 8.5


10 * BC-4 consisted of α -boswellic acid acetate
and β -boswellic acid acetate in an approximately 1:1
ratio.

** Animals surviving to end of experiment (day 30).

15 Obviously, numerous modifications and variations
of the present invention are possible in light of the
above teachings. It is therefore to be understood that
within the scope of the appended claims, the invention
may be practiced otherwise than as specifically
described herein.

Claims

1. A method for inhibiting topoisomerase I, which comprises contacting topoisomerase I in vitro or in vivo with an inhibitory effective amount of a compound selected from the group consisting of those having the following formulas:



- wherein R^1 is $-\text{COOR}^4$, where R^4 is a mono; di; or trisaccharide; $-\text{H}$; C_{1-4} alkyl; C_{2-4} alkenyl; C_{3-4} alkynyl; C_6-C_8 aryl which is unsubstituted or is substituted by halogen, methoxy, ethoxy, sulfonamido, amino, mono- or di- C_{1-4} -alkyl-amino, mono- or di-acetylamino, C_{1-4} alkyl, C_{2-4} alkenyl,

or

- R^1 is $-\text{CONH}_2$; $-\text{CONHR}^5$; or $-\text{CONR}_2^5$, where R^5 is a mono; di; or trisaccharide; $-\text{CH}_3$; $-\text{CH}_2\text{COOH}$; $-\text{CH}_2\text{CH}_2\text{COOH}$; C_{2-8} alkyl; C_{2-8} alkenyl; C_{2-8} alkynyl; or C_6-8 aryl which is unsubstituted or is substituted by halogen, methoxy, ethoxy, sulfonamido, amino, mono- or

-35-

di-C₁₋₄-alkyl-amino, mono- or di-acetylamino, C₁₋₄ alkyl, C₂₋₄ alkenyl, and

R² and R³ may be combinations of hydrogen or R⁵,

with -H, -OR⁴, -NH₂, -NHR⁵, -NHR₂⁵, $\overset{\text{O}}{\parallel}\text{-OCR}^5$ or $\overset{\text{O}}{\parallel}\text{-NHCR}^5$,

5 wherein R⁴ and R⁵ are as defined above,

or

R² and R³ together may be =O or =N-OR⁴, wherein R⁴ is as defined above, and

R⁶ and R⁷ may be combinations of hydrogen or R⁵,

10 with -H, -OR⁴, -NH₂, -NHR⁵, -NHR₂⁵, $\overset{\text{O}}{\parallel}\text{-OCR}^5$ or $\overset{\text{O}}{\parallel}\text{-NHCR}^5$,
wherein R⁴ and R⁵ are as defined above,

or

R⁶ and R⁷ together may be =O or =N-OR⁴, wherein R⁴ is as defined above, and

15 pharmaceutically acceptable salts thereof.

2. The method according to Claim 1, wherein R¹ is -COOR⁴, wherein R⁴ is -H, C₁₋₄ alkyl, or NH₂.

3. The method according to Claim 1, wherein R³ is -H and R² is -H, -OH, -OAc, -OCOC₂H₅ or -NHAc.


20 4. The method of Claim 1, wherein R⁶ = R⁷ = R³ = H, R² = OH, and R¹ = COOH.

5. The method of Claim 1, wherein $R^6 = R^7 = R^3 = H$, $R^2 = OCOCH_3$, and $R^1 = COOH$.


6. The method of Claim 1, wherein $R^6 = R^7 = R^3 = H$, $R^2 = OH$, and $R^1 = COOH$.

- 5 7. A method for inhibiting topoisomerase II, which comprises contacting topoisomerase II in vitro or in vivo with an inhibitory effective amount of a compound selected from the group consisting of those having the following formulas:


10




C



D



E



F

-37-

wherein R^1 is $-\text{COOR}^4$, where R^4 is a mono; di; or trisaccharide; $-\text{H}$; C_{1-4} alkyl; C_{2-4} alkenyl; C_{3-4} alkynyl; C_6-C_8 aryl which is unsubstituted or is substituted by halogen, methoxy, ethoxy, sulfonamido, amino, mono- or di- C_{1-4} -alkyl-amino, mono- or di-acetylamino, C_{1-4} alkyl, C_{2-4} alkenyl,

or

R^1 is $-\text{CONH}_2$; $-\text{CONHR}^5$; or $-\text{CONR}_2^5$, where R^5 is a mono; di; or trisaccharide; $-\text{CH}_3$; $-\text{CH}_2\text{COOH}$; $-\text{CH}_2\text{CH}_2\text{COOH}$; C_{2-8} alkyl; C_{2-8} alkenyl; C_{2-8} alkynyl; C_{6-8} aryl which is unsubstituted or is substituted by halogen, methoxy, ethoxy, sulfonamido, amino, mono- or di- C_{1-4} -alkyl-amino, mono- or di-acetylamino, C_{1-4} alkyl, C_{2-4} alkenyl, and

R^2 and R^3 may be combinations of hydrogen or R^5 ,

with $-\text{H}$, $-\text{OR}^4$, $-\text{NH}_2$, $-\text{NHR}^5$, $-\text{NHR}_2^5$, $-\overset{\text{O}}{\parallel}\text{CR}^5$ or $-\overset{\text{O}}{\parallel}\text{NHR}^5$,
wherein R^4 and R^5 are as defined above,

or

R^2 and R^3 together may be $=\text{O}$ or $=\text{N}-\text{OR}^4$, wherein R^4 is as defined above, and

R^6 and R^7 may be combinations of hydrogen or R^5 ,

with $-\text{H}$, $-\text{OR}^4$, $-\text{NH}_2$, $-\text{NHR}^5$, $-\text{NHR}_2^5$, $-\overset{\text{O}}{\parallel}\text{CR}^5$ or $-\overset{\text{O}}{\parallel}\text{NHR}^5$,
wherein R^4 and R^5 are as defined above,

or

-38-

R⁶ and R⁷ together may be =O or =N-OR⁴, wherein R⁴ is as defined above, and

pharmaceutically acceptable salts thereof.

8. The method according to Claim 7, wherein R¹ is
5 -COOR⁴, wherein R⁴ is -H, C₁₋₄ alkyl, or NH₂.





9. The method according to Claim 7, wherein R³ is -H, and R² is -H, -OH, -OAc, -OCOC₂H₅ or -NHAc.

10. The method of Claim 7, wherein R⁶ = R⁷ = R³ = H, R² = OH, and R¹ = COOH.

10 11. The method of Claim 7, wherein R⁶ = R⁷ = R³ = H, R² = OCOCH₃, and R¹ = COOH.

12. A composition for treatment of a mammal suffering from a cancer selected from the group consisting of small cell lung cancer, testicular
15 cancer, lymphoma, leukemia, esophageal cancer, stomach cancer, colon cancer, breast cancer, central nervous system cancer, liver cancer and prostate cancer, which comprises:

a compound selected from the group consisting of
20 those having the following formulas:



wherein R^1 is $-\text{COOR}^4$, where R^4 is a mono; di; or trisaccharide; $-\text{H}$; C_{1-4} alkyl; C_{2-4} alkenyl;

- 5 C_{3-4} alkynyl; C_6-C_8 aryl which is unsubstituted or is substituted by halogen, methoxy, ethoxy, sulfonamido, amino, mono- or di- C_{1-4} -alkyl-amino, mono- or di-acetylamino, C_{1-4} alkyl, or C_{2-4} alkenyl,

or

- 10 R^1 is $-\text{CONH}_2$; $-\text{CONHR}^5$; or $-\text{CONR}_2^5$ where R^5 is a mono; di; or trisaccharide; $-\text{CH}_3$; $-\text{CH}_2\text{COOH}$; $-\text{CH}_2\text{CH}_2\text{COOH}$; C_{2-8} alkyl; C_{2-8} alkenyl; C_{2-8} alkynyl; or C_{6-8} aryl which is unsubstituted or is substituted by halogen, methoxy, ethoxy, sulfonamido, amino, mono- or
- 15 di- C_{1-4} -alkyl-amino, mono- or di-acetylamino, C_{1-4} alkyl, C_{2-4} alkenyl, and

R^2 and R^3 may be combinations of hydrogen or R^5 ,

with $-\text{H}$, $-\text{OR}^4$, $-\text{NH}_2$, $-\text{NHR}^5$, $-\text{NHR}_2^5$, $-\text{OCR}^5$ or $-\text{NHCOR}^5$,

wherein R^4 and R^5 are as defined above,

or

R^2 and R^3 together may be $=O$ or $=N-OR^4$, wherein R^4 is as defined above, and

5 R^6 and R^7 may be combinations of hydrogen or R^5 ,

with $-H$, $-OR^4$, $-NH_2$, $-NHR^5$, $-NHR^5_2$, $-OCR^5$ or $-NHCR^5$,
 $\begin{array}{c} O \\ || \\ -OCR^5 \end{array}$ or $\begin{array}{c} O \\ || \\ -NHCR^5 \end{array}$,

wherein R^4 and R^5 are as defined above,


or



10 R^6 and R^7 together may be $=O$ or $=N-OR^4$, wherein R^4 is as defined above, and

pharmaceutically acceptable salts thereof,

in combination with an agent for targeting said compound to the site where said cancer is localized in said mammal.

15 13. A method for inducing cellular differentiation, which comprises contacting a cancerous cell with an effective amount of a compound selected from the group consisting of those having the following formulas:





wherein R^1 is $-\text{COOR}^4$, where R^4 is a mono; di; or trisaccharide; $-\text{H}$; C_{1-4} alkyl; C_{2-4} alkenyl; C_{3-4} alkynyl; C_6-C_8 aryl which is unsubstituted or is substituted by halogen, methoxy, ethoxy, sulfonamido, amino, mono- or di- C_{1-4} -alkyl-amino, mono- or di-acetylamino, C_{1-4} alkyl, C_{2-4} alkenyl,

or

R^1 is $-\text{CONH}_2$; $-\text{CONHR}^5$; or $-\text{CONR}_2^5$, where R^5 is a mono; di; or trisaccharide; $-\text{CH}_3$; $-\text{CH}_2\text{COOH}$; $-\text{CH}_2\text{CH}_2\text{COOH}$; C_{2-8} alkyl; C_{2-8} alkenyl; C_{2-8} alkynyl; or C_6-8 aryl which is unsubstituted or is substituted by halogen, methoxy, ethoxy, sulfonamido, amino, mono- or di- C_{1-4} -alkyl-amino, mono- or di-acetylamino, C_{1-4} alkyl, C_{2-4} alkenyl, and

R^2 and R^3 may be combinations of hydrogen or R^5 ,

with $-\text{H}$, $-\text{OR}^4$, $-\text{NH}_2$, $-\text{NHR}^5$, $-\text{NHR}_2^5$, $-\text{OCR}^5$ or $-\text{NHCR}^5$, wherein R^4 and R^5 are as defined above,

or


R^2 and R^3 together may be $=\text{O}$ or $=\text{N-OR}^4$, wherein R^4 is as defined above, and

R^6 and R^7 may be combinations of hydrogen or R^5 ,
 with $-H$, $-OR^4$, $-NH_2$, $-NHR^5$, $-NHR^5_2$, $-O\overset{\overset{O}{\parallel}}{C}R^5$ or $-NE\overset{\overset{O}{\parallel}}{C}R^5$,
 wherein R^4 and R^5 are as defined above,
 or

- 5 R^6 and R^7 together may be $=O$ or $=N-OR^4$, wherein R^4
 is as defined above, and

pharmaceutically acceptable salts thereof.

14. A method of treating a cancer selected from
 the group consisting of small cell lung cancer,
 10 testicular cancer, lymphoma, leukemia, esophageal
 cancer, stomach cancer, colon cancer, breast cancer,
 central nervous system cancer, liver cancer and
 prostate cancer, which comprises administering to a
 mammal in need thereof an effective amount of a
 15 composition containing as the active ingredient therein
 a compound selected from the group consisting of those
 having the following formulas:



wherein R^1 is $-\text{COOR}^4$, where R^4 is a mono; di; or trisaccharide; $-\text{H}$; C_{1-4} alkyl; C_{2-4} alkenyl; C_{3-4} alkynyl; C_6-C_8 aryl which is unsubstituted or is substituted by halogen, methoxy, ethoxy, sulfonamido, amino, mono- or di- C_{1-4} -alkyl-amino, mono- or di-acetylamino, C_{1-4} alkyl, C_{2-4} alkenyl,

or

R^1 is $-\text{CONH}_2$; $-\text{CONHR}^5$; or $-\text{CONR}_2^5$, where R^5 is a mono; di; or trisaccharide; $-\text{CH}_3$; $-\text{CH}_2\text{COOH}$; $-\text{CH}_2\text{CH}_2\text{COOH}$; C_{2-8} alkyl; C_{2-8} alkenyl; C_{2-8} alkynyl; or C_{6-8} aryl which is unsubstituted or is substituted by halogen, methoxy, ethoxy, sulfonamido, amino, mono- or di- C_{1-4} -alkyl-amino, mono- or di-acetylamino, C_{1-4} alkyl, C_{2-4} alkenyl, and

R^2 and R^3 may be combinations of hydrogen or R^5 ,

with $-\text{H}$, $-\text{OR}^4$, $-\text{NH}_2$, $-\text{NHR}^5$, $-\text{NHR}_2^5$, $-\text{OCR}^5$ or $-\text{NHCR}^5$,
 wherein R^4 and R^5 are as defined above,

or

R^2 and R^3 together may be $=\text{O}$ or $=\text{N}-\text{OR}^4$, wherein R^4 is as defined above, and

R^6 and R^7 may be combinations of hydrogen or R^5 ,

with $-\text{H}$, $-\text{OR}^4$, $-\text{NH}_2$, $-\text{NHR}^5$, $-\text{NHR}_2^5$, $-\text{OCR}^5$ or $-\text{NHCR}^5$,
 wherein R^4 and R^5 are as defined above,


or

-44-


R^6 and R^7 together may be $=O$ or $=N-OR^4$, wherein R^4 is as defined above, and

pharmaceutically acceptable salts thereof.

1/7

A-1. $R = \text{CH}_3\text{COO}$ A-2. $R = \text{OH}$

(A)

FIG. 1AB-1. $R = \text{CH}_3\text{COO}$ B-2. $R = \text{OH}$

(B)

FIG. 1B

2/7









FIG. 2

3/7

*FIG. 3A**FIG. 3B**FIG. 3C**FIG. 3D*


4/7



5/7

FIG. 5A**Topoisomerase I Relaxation Assay**

A B C D E F G H I J K L M

**FIG. 6A****Topoisomerase II Unknotting Assay**

A B C D E F G H I J K L M



6/7

Column No.	DNA	Topoisomerase I Enzyme (units)	Drug Concentration (μ M)	Activity
A	pBR322	0	0	-
B	"	0.75	0	-
C	"	1.5	0	-
D	"	3.0	0	-
E	pBR322	3.0	Camptothecin (1.6 μ M)	-
F	"	3.0	Camptothecin (4.0 μ M)	-
G	"	3.0	Camptothecin (10 μ M)	++
H	pBR322	3.0	TS-A-14-I (1.6 μ M)	-
I	"	3.0	TS-A-14-I (4.0 μ M)	+
J	"	3.0	TS-A-14-I (10.0 μ M)	++
K	pBR322	3.0	TS-A-14-II (1.6 μ M)	-
L	"	3.0	TS-A-14-II (4.0 μ M)	-
M	"	3.0	TS-A-14-II (10.0 μ M)	++

*3.0 units of topoisomerase I enzyme showed full activity and was employed as standard conditions for drug screening.

FIG. 5B

7/7

Column No.	DNA	Topoisomerase II Enzyme (units)	Drug Concentration (μ M)	Activity
A	P4 (knotted)	0	0	-
B	"	0.75	0	-
C	"	1.5	0	-
D	"	3.0	0	-
E	P4 (knotted)	3.0	VP-16 (25)	-
F	"	3.0	VP-16 (50)	-
G	"	3.0	VP-16 (100)	++
H	P4 (knotted)	3.0	TS-A-14-I (0.625)	-
I	"	3.0	TS-A-14-I (2.5)	-
J	"	3.0	TS-A-14-I (10)	++
K	P4 (knotted)	3.0	TS-A-14-II (0.625)	-
L	"	3.0	TS-A-14-II (2.5)	-
M	"	3.0	TS-A-14-II (10)	++

FIG. 6B

INTERNATIONAL SEARCH REPORT

International Application No. **PCT/US89/03581**

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) ⁶ According to International Patent Classification (IPC) or to both National Classification and IPC IPC(4): A61K 31/70; A61K 31/21; A61K 31/195; A61K 31/19; A61K 31/18; See Continuation sheet 1 U.S.C1.: 514/33; 514/510; 514/563; 514/564; 514/569; 514/602; See Continuation sheet 1								
II. FIELDS SEARCHED <div style="text-align: center; border-top: 1px solid black; border-bottom: 1px solid black; margin: 5px 0;">Minimum Documentation Searched ⁷</div> <table style="width: 100%; border-collapse: collapse;"> <tr> <th style="width: 25%; border: 1px solid black; text-align: left;">Classification System</th> <th style="border: 1px solid black; text-align: left;">Classification Symbols</th> </tr> <tr> <td style="border: 1px solid black; vertical-align: top; padding: 5px;">U.S.</td> <td style="border: 1px solid black; vertical-align: top; padding: 5px;">514/33; 514/510; 514/563; 514/564; 514/569; 514/602; 514/603; 514/620; 514/752; 514/753</td> </tr> </table> <div style="border: 1px solid black; padding: 5px; margin-top: 5px; text-align: center;"> Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched ⁸ </div>			Classification System	Classification Symbols	U.S.	514/33; 514/510; 514/563; 514/564; 514/569; 514/602; 514/603; 514/620; 514/752; 514/753		
Classification System	Classification Symbols							
U.S.	514/33; 514/510; 514/563; 514/564; 514/569; 514/602; 514/603; 514/620; 514/752; 514/753							
III. DOCUMENTS CONSIDERED TO BE RELEVANT ⁹ <table style="width: 100%; border-collapse: collapse;"> <tr> <th style="width: 10%; border: 1px solid black; text-align: left;">Category [*]</th> <th style="width: 70%; border: 1px solid black; text-align: left;">Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²</th> <th style="width: 20%; border: 1px solid black; text-align: left;">Relevant to Claim No. ¹³</th> </tr> <tr> <td style="border: 1px solid black; vertical-align: top; text-align: center; padding: 10px;">Y</td> <td style="border: 1px solid black; vertical-align: top; padding: 10px;">US. A 4 501,734 (TANAKA ET AL) published 26 February 1985. see entire reference.</td> <td style="border: 1px solid black; vertical-align: top; text-align: center; padding: 10px;">1-14</td> </tr> </table>			Category [*]	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³	Y	US. A 4 501,734 (TANAKA ET AL) published 26 February 1985. see entire reference.	1-14
Category [*]	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³						
Y	US. A 4 501,734 (TANAKA ET AL) published 26 February 1985. see entire reference.	1-14						
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>[*] Special categories of cited documents: ¹⁰</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&" document member of the same patent family</p> </div> </div>								
IV. CERTIFICATION <table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%; border: 1px solid black; padding: 5px;"> Date of the Actual Completion of the International Search 30 NOVEMBER 1989 </td> <td style="width: 50%; border: 1px solid black; padding: 5px;"> Date of Mailing of this International Search Report <div style="text-align: center; font-size: 1.2em; font-weight: bold;">19 DEC 1989</div> </td> </tr> <tr> <td style="border: 1px solid black; padding: 5px;"> International Searching Authority RO/US </td> <td style="border: 1px solid black; padding: 5px;"> Signature of Authorized Officer <div style="text-align: center;"> JEROME GOLDBERG </div> </td> </tr> </table>			Date of the Actual Completion of the International Search 30 NOVEMBER 1989	Date of Mailing of this International Search Report <div style="text-align: center; font-size: 1.2em; font-weight: bold;">19 DEC 1989</div>	International Searching Authority RO/US	Signature of Authorized Officer <div style="text-align: center;"> JEROME GOLDBERG </div>		
Date of the Actual Completion of the International Search 30 NOVEMBER 1989	Date of Mailing of this International Search Report <div style="text-align: center; font-size: 1.2em; font-weight: bold;">19 DEC 1989</div>							
International Searching Authority RO/US	Signature of Authorized Officer <div style="text-align: center;"> JEROME GOLDBERG </div>							

Form PCT/ISA/210 (second sheet) (Rev. 11-87)

PCT/US89/03581

I CLASSIFICATION OF SUBJECT MATTER (CONTINUED)

IPC(4): A61K 31/165; A61k 31/03

U.S Cl.: 514/603; 514/617; 514/620; 514/752; 514/753

THIS PAGE BLANK (USPTO)